Abstract 2119: DCLK1 regulates ATR-DNA damage response for KRAS mutant lung cancer drug resistance and stemness

2019 ◽  
Author(s):  
Courtney Houchen ◽  
Janani Panneerselvam ◽  
Priyanga Mohandoss ◽  
Nathaniel Weygant ◽  
Randal May ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Damage ◽  
Drug Resistance ◽  
Dna Damage Response ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Damage Response

Abstract 2119: DCLK1 regulates ATR-DNA damage response for KRAS mutant lung cancer drug resistance and stemness

2019 ◽  
Author(s):  
Courtney Houchen ◽  
Janani Panneerselvam ◽  
Priyanga Mohandoss ◽  
Nathaniel Weygant ◽  
Randal May ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Damage ◽  
Drug Resistance ◽  
Dna Damage Response ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Damage Response

scholarly journals Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma

2020 ◽  
Vol 21 (14) ◽  
pp. 4910 ◽  
Author(s):  
Alessandra Ferri ◽  
Venturina Stagni ◽  
Daniela Barilà
Keyword(s):  
Dna Damage ◽  
Dna Damage Response ◽  
Kinase Inhibitors ◽  
Cancer Drug ◽  
Special Focus ◽  
Dna Repair Mechanisms ◽  
Cancer Drug Resistance ◽  
Damage Response ◽  
Repair Mechanisms ◽  
Future Therapy

Glioblastoma multiforme (GBM) is a severe brain tumor whose ability to mutate and adapt to therapies is at the base for the extremely poor survival rate of patients. Despite multiple efforts to develop alternative forms of treatment, advances have been disappointing and GBM remains an arduous tumor to treat. One of the leading causes for its strong resistance is the innate upregulation of DNA repair mechanisms. Since standard therapy consists of a combinatory use of ionizing radiation and alkylating drugs, which both damage DNA, targeting the DNA damage response (DDR) is proving to be a beneficial strategy to sensitize tumor cells to treatment. In this review, we will discuss how recent progress in the availability of the DDR kinase inhibitors will be key for future therapy development. Further, we will examine the principal existing DDR inhibitors, with special focus on those currently in use for GBM clinical trials.

scholarly journals Computational methods for the analysis and prediction of drug resistance in EGFR-mutated non-small cell lung cancer patients

2021 ◽  
Author(s):  
Rizwan Qureshi
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Computational Methods ◽  
Review Paper ◽  
Small Cell ◽  
Cancer Drug ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Cancer Drug Resistance ◽  
Egfr Mutated

This is a review paper for the analysis and prediction of lung cancer drug resistance. We explore several computational methods, that can provide, biological insights for the analysis, visualization and prediction of lung cancer drug resistance.

Sign in / Sign up

Export Citation Format

Share Document